Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common blood pressure pill protect insulin cells in kids with type 1 diabetes?

NCT ID NCT07804849

Disease control Sponsor: Ain Shams University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This trial tests whether verapamil, a blood pressure drug, can protect the pancreas cells that make insulin in children and teens newly diagnosed with type 1 diabetes. Participants aged 10 to 18 will take verapamil or a placebo daily for 24 weeks. Researchers will measure how much insulin the body still makes, blood sugar control, and daily insulin needs to see if verapamil slows the loss of insulin production.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
verapamil (oral)
What this could lead to
If verapamil preserves insulin-making cells, children with type 1 diabetes might keep more natural insulin production, easing blood sugar control and reducing daily insulin doses.
What could go wrong
This is a mid-stage trial with 70 participants, so results may not apply broadly. Verapamil can cause side effects like low blood pressure or constipation, and it may not slow the immune attack on beta cells.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

10 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children and adolescents aged 10-18 years. * Newly diagnosed type 1 diabetes mellitus (within 6 weeks of diagnosis, defined as the day of starting insulin therapy). * Presence of at least two positive islet autoantibody (anti glutamic acid decarboxylase antibodies, anti- tyrosine phosphataseantibodies ,anti- zinc transporter 8 protein antibodies , or anti-insulin antibodies). * Ability to comply with study procedures. Exclusion Criteria: * Previous diagnosis of other endocrine disorders or autoimmune disorder (e.g. autoimmune thyroiditis). * Current or planned use of medications that might affect glucose metabolism (e.g., corticosteroids, immunomodulators). * Known allergy or intolerance to verapamil. * Cardiac conduction abnormalities, heart block, or significant cardiac disease. * Systolic or diastolic blood pressure \< 5th percentile for age and gender. * Severe hepatic or renal impairment. * Participation in another interventional clinical trial. * Inability to follow the protocol for any reason as determined by the investigator. * Elevated liver enzymes \>1.5 × upper limit of normal at screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 1 diabetes mellitus are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 1 diabetes mellitus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ain Shams University

    RECRUITING

    Cairo, 11375, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.